SCHEMBL24930878

SCHEMBL24930878

CCc1cnc(C(C)C)c(C(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.33
GSR P00390 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32
CAPN1 P07384 1/20 0.32
PARP1 P09874 1/20 0.31
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.30
TDP1 Q9NUW8 1/20 0.30
GABRA1 P14867 1/20 0.30
GABRB1 P18505 1/20 0.30
GABRA5 P31644 1/20 0.30
GABRA3 P34903 1/20 0.30
GABRA2 P47869 1/20 0.30
GABRB2 P47870 1/20 0.30
GABRA4 P48169 1/20 0.30
GABRA6 Q16445 1/20 0.30
RXRA P19793 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15417377 0.80 DHFR (0.33) DHFRGSRPARP1NOS3NOS1
SCHEMBL12749933 0.80 NOS3 (0.33) DHFRCYP1A2CYP2A6CAPN1PARP1
SCHEMBL10981032 0.80 CAPN1 (0.35) DHFRCYP1A2CYP2A6CAPN1PARP1
SCHEMBL25884479 0.79 GSR (0.53) DHFRGSRNOS1
SCHEMBL18400150 0.78 TDP1 (0.33) CYP1A2CYP2A6CAPN1PARP1L3MBTL1
SCHEMBL21105492 0.78 PANK3 (0.38) CYP1A2CYP2A6CAPN1PARP1RXRA
SCHEMBL14948934 0.78 CHRNB2 (0.33) DHFRGSRCYP1A2GABRA1GABRB1
SCHEMBL21076523 0.74 DHFR (0.31) DHFRGABRA1KDM4E
SCHEMBL20642370 0.73 PDE10A (0.31) DHFR
SCHEMBL12796020 0.72 GABRA1 (0.39) CYP1A2GABRA1GABRB1GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731956-B2 Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors ALUMIS INC. (US) 2023-08-22 US disclosed
US-20230021554-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230021554-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 DHFR 3668/4885GSR 4756/4885CYP1A2 3164/4885
US-11731956-B2 Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors TYK2, JAK1, JAK3 DHFR 3314/4885GSR 4641/4885CYP1A2 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.